Industry Press Releases

DelMar Pharmaceuticals announces Upcoming Investor and Scientific Conference Presentations

Thursday, May 28, 2015
Pressreleases

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that it will be presenting at several upcoming investor and scientific conferences.

   

Event:

Fourth Annual SeeThru Equity Microcap Investor Conference

 

Presentation with Audio Webcast

Date:

Thursday, May 28, 2015

Time:

8:30 a.m. EDT

Location:

Convene Grand Central, New York, NY

   

Event:

AACR Advances in Brain Cancer Research Conference

 

Poster Presentation: Dianhydrogalactitol inhibits the growth of glioma stem and non-stem cultures, including temozolomide-resistant cell lines, in vitro and in vivo

Date:

Thursday, May 28, 2015

Time:

1:45-4:30 p.m. EDT

Location:

Omni Shoreham Hotel, Washington, DC

   

Event:

Sachs Immuno-Oncology: BD&L and Investment Forum

 

Presentation and Panel Participation: Pharma-Biotech Business Development & Licensing Panel

Date:

Friday, May 29, 2015

Location:

Hyatt Chicago Magnificent Mile, Chicago, IL

   

Event:

ASCO Annual Meeting

 

Poster Presentation: "Phase I/II Study of Dianhydrogalactitol in Patients with Recurrent Malignant Glioma" (abstract no. e19145)

Date:

Monday, June 1, 2015

Time:

1:15-4:45 p.m. CDT

Location:

McCormick Place, Chicago, IL

   
 

A second abstract, entitled, "Activity of Dianhydrogalactitol Alone or with Platinum Drugs Against Non-small Cell Lung Cancer Cell Lines," (abstract no. e19145) will be published online at www.asco.org and jco.ascopubs.org

   

Event:             

LD Micro Invitational

 

Presentation with Audio Webcast

Date:              

Wednesday, June 3, 2015

Time:              

8:30 a.m. PDT / 11:30 a.m. EDT

Location:        

Luxe Sunset Boulevard, Los Angeles, CA

Live audio webcasts of the SeeThru Equity and LD Micro investor conference presentations will be available by accessing the DelMar's IR Calendar in the Investors section of the Company's website (www.DelMarPharma.com). The webcast replays will be available approximately two hours after the presentation ends and will be accessible for one month.

DelMar's data presentations from the AACR Advances in Brain Cancer Research and ASCO Annual meeting will be available on the Company's website on the Scientific Publications & Presentations of its website following each respective conference presentation.

About VAL-083

VAL-083 is a "first-in-class", small-molecule chemotherapeutic. In more than 40 Phase 1 and 2 clinical studies sponsored by the U.S. National Cancer Institutes, VAL-083 demonstrated safety and efficacy in treating a number of cancers including lung, brain, cervical, ovarian tumors and leukemia. VAL-083 is approved in China for the treatment of chronic myelogenous leukemia and lung cancer and has received orphan drug designation in Europe and the U.S. for the treatment of gliomas.

As a potential treatment for glioblastoma, VAL-083's mechanism of action appears to be unaffected by the expression of MGMT, a DNA repair enzyme that causes chemotherapy resistance to front-line treatment with Temodar® (temozolomide).

DelMar is currently studying VAL-083 in a multi-center Phase I/II clinical trial for patients with refractory glioblastoma multiforme in accordance with the protocol that has been filed with the U.S. Food and Drug Administration (FDA).  Eligible GBM patients must have failed both Avastin® (bevacizumab) and Temodar® (temozolomide) unless either of these therapies was contraindicated. (ClinicalTrials.gov Identifier NCT01478178).

About DelMar Pharmaceuticals, Inc.

DelMar Pharmaceuticals, Inc. was founded to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company's lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.

 

prnewswire.com

Other Press Releases